The role of protein tyrosine phosphatases regulating Eph RTK-signalling and modulating invasive tumour cell properties.
The role of protein tyrosine phosphatases regulating Eph RTK-signalling and modulating invasive tumour cell properties.
批准号:
nhmrc : 436774
负责人:
A/Pr Martin Lackmann
金额:
$20.26万
依托单位:
依托单位国家:
澳大利亚
项目类别:
NHMRC Project Grants
财政年份:
2007
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2007-01-01 至 2009-12-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The Ephs and interacting ephrins are proteins on the cell surface, which enable orientation of cells that move within the body tissues and organs, but also in tumours. Eph proteins have tyrosine kinase enzyme activity that becomes active after binding ephrins on neighbouring cells. Once active, they instruct these cells to change their shape and their adhesion to the substratum or between each other, and to become more motile. In adult organisms Ephs and ephrins are low in most cells, but they re-appear in many tumors. For example, when normal cells in the skin (melanocytes) become tumor cells, they often will have Ephs and ephrins on their surface. It is believed that these proteins will now affect if these melanoma cells will migrate and to which locations within the body. In our studies we will examine what controls the activity of Eph proteins. In particular, a class of enzymes called tyrosine phosphatases are known to regulate the function of tyrosine kinase receptors, however it is not clear which particular phosphatase regulates EphA3, the focus of our studies. We will find out, which set of phosphatases regulates EphA3 function and whether exposure to oxidative conditions, such as UV radiation, also activates Ephs and instructs tumour cells to become more motile and to invade other areas of the body. The understanding of this mechanism will help to understand the cause of cancers such as melanoma and might offer possibilities to optimise new strategies for its treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Antibody-based inhibition of ADAM10 as cancer immunotherapy
-
批准号:nhmrc : 1067609
-
项目类别:Project Grants
-
资助金额:$43.53万
-
财政年份:2014
-
负责人:A/Pr Martin Lackmann
-
依托单位:
Control of gastrointestinal tumour progression by therapeutic interference with myeloid derived cells
-
批准号:nhmrc : 1067244
-
项目类别:Project Grants
-
资助金额:$50.59万
-
财政年份:2014
-
负责人:A/Pr Martin Lackmann
-
依托单位:
Can inhibition of myeloid cell function suppress gastro-intestinal cancer?
-
批准号:nhmrc : GNT1067244
-
项目类别:Project Grants
-
资助金额:$72.75万
-
财政年份:2014
-
负责人:A/Pr Martin Lackmann
-
依托单位:
Inhibiting tumour growth by targeting EphA3 and disrupting tumour stromal and vascular microenvironment
-
批准号:nhmrc : 1049942
-
项目类别:Project Grants
-
资助金额:$43.02万
-
财政年份:2013
-
负责人:A/Pr Martin Lackmann
-
依托单位:
Receptor tyrosine kinase function as molecular target in cancer.
-
批准号:nhmrc : 1003908
-
项目类别:NHMRC Research Fellowships
-
资助金额:$27.72万
-
财政年份:2011
-
负责人:A/Pr Martin Lackmann
-
依托单位:
EphA3-modulated cell positioning in tumour invasion and neovascularisation.
-
批准号:nhmrc : 384241
-
项目类别:NHMRC Project Grants
-
资助金额:$43.16万
-
财政年份:2006
-
负责人:A/Pr Martin Lackmann
-
依托单位:
Research Fellowship - Grant ID:384113
-
批准号:nhmrc : 384113
-
项目类别:NHMRC Research Fellowships
-
资助金额:$36.6万
-
财政年份:2006
-
负责人:A/Pr Martin Lackmann
-
依托单位:
Functional analysis of the molecular switch that regulates ADAM10-mediated cleavage of RTK ligands in tumour cells.
-
批准号:nhmrc : 384242
-
项目类别:NHMRC Project Grants
-
资助金额:$30.49万
-
财政年份:2006
-
负责人:A/Pr Martin Lackmann
-
依托单位:
The Role of Eph/ephrin clustering and trafficking in control of tumour cell invasion
-
批准号:nhmrc : 334085
-
项目类别:NHMRC Project Grants
-
资助金额:$29.31万
-
财政年份:2005
-
负责人:A/Pr Martin Lackmann
-
依托单位:
Stage II in the development of Eph/ephrin based tumor targeting reagents: Optimisation of drug efficacy and delivery
-
批准号:nhmrc : 284418
-
项目类别:NHMRC Development Grants
-
资助金额:$13.61万
-
财政年份:2004
-
负责人:A/Pr Martin Lackmann
-
依托单位:
Development of anti-metastatic and tumour targeting reagents by design of inhibitors to specific Eph/ephrin cell-cell
-
批准号:nhmrc : 234712
-
项目类别:NHMRC Development Grants
-
资助金额:$13.34万
-
财政年份:2003
-
负责人:A/Pr Martin Lackmann
-
依托单位:
Development and evaluation of biological reagents targeting and inhibiting function of the EphA3 receptor on tumor cells
-
批准号:nhmrc : 234707
-
项目类别:NHMRC Project Grants
-
资助金额:$32.71万
-
财政年份:2003
-
负责人:A/Pr Martin Lackmann
-
依托单位:
Signal transduction pathways of EphA receptor tyrosine kinases
-
批准号:nhmrc : 991280
-
项目类别:NHMRC Project Grants
-
资助金额:$12.15万
-
财政年份:1999
-
负责人:A/Pr Martin Lackmann
-
依托单位:
国内基金
海外基金
登录
查看更多内容
子宫内膜间质与巨噬细胞之间通过Protein S-MerTK-Apelin信号对
话促进子宫腺肌病蜕膜化缺陷的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:吕海宁
-
依托单位:
有翅与无翅蚜虫差异分泌唾液蛋白Cuticular protein在调控植物细胞壁免疫中的功能
-
批准号:32372636
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2023
-
负责人:郭慧娟
-
依托单位:
原发性开角型青光眼中SIPA1L1促进小梁网细胞外基质蛋白累积升高眼压的作用机制
-
批准号:82371054
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:郭涛
-
依托单位:
胆固醇合成蛋白CYP51介导线粒体通透性转换诱发Th17/Treg细胞稳态失衡在舍格伦综合征中的作用机制研究
-
批准号:82370976
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:郑凌艳
-
依托单位:
G蛋白偶联受体GPR110调控Lp-PLA2抑制非酒精性脂肪性肝炎的作用及机制研究
-
批准号:82370865
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:黄哲
-
依托单位:
细胞周期蛋白依赖性激酶Cdk1介导卵母细胞第一极体重吸收致三倍体发生的调控机制研究
-
批准号:82371660
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:魏喆
-
依托单位:
转运蛋白RCP调控巨噬细胞脂肪酸氧化参与系统性红斑狼疮发病的机制研究
-
批准号:82371798
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:叶俊娜
-
依托单位:
紧密连接蛋白PARD3下调介导黏膜上皮屏障破坏激活STAT3/SNAI2通路促进口腔白斑病形成及进展的机制研究
-
批准号:82370954
-
项目类别:面上项目
-
资助金额:47.00万元
-
批准年份:2023
-
负责人:沈雪敏
-
依托单位:
新型小分子蛋白—人肝细胞生长因子三环域(hHGFK1)抑制破骨细胞及治疗小鼠骨质疏松的疗效评估与机制研究
-
批准号:82370885
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:姚晨
-
依托单位:
蛋白精氨酸甲基化转移酶PRMT5调控PPARG促进巨噬细胞M2极化及其在肿瘤中作用的机制研究
-
批准号:82371738
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:郑英霞
-
依托单位: